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Background:  Stromelysin belongs to a family of zinc-dependent
endopeptidases referred to as matrix metalloproteinases (MMPs, matrixins)
because of their capacity for selective degradation of various components 
of the extracellular matrix. Matrixins play key roles in diseases as diverse as
arthritis and cancer and hence are important targets for therapeutic intervention.
Results:  The crystal structure of the stromelysin catalytic domain (SCD) with
bound hydroxamate inhibitor, solved by multiple isomorphous replacement,
shows a deep S1′ specificity pocket which explains differences in inhibitor
binding between the collagenases and stromelysin. The binding of calcium ions
by loops at the two ends of a b-strand which marks the boundary of the active
site provides a structural rationale for the importance of these cations for stability
and catalytic activity. Major differences between the matrixins are clustered in
two regions forming the entrance to the active site and hence may be
determinants of substrate selectivity.
Conclusions:  Structural comparisons of SCD with representative members of
the metalloproteinase superfamily clearly highlight the conservation of key
secondary structural elements, in spite of major variations in the sequences
including insertions and deletions of functional domains. However, the 
three-dimensional structure of SCD, which is generally closely related to the
collagenases, shows significant differences not only in the peripheral regions but
also in the specificity pockets; these latter differences should facilitate the
rational design of specific inhibitors.
Introduction
The family of matrix metalloproteinases (MMPs), of
which stromelysin-1 (MMP-3) is a member, includes key
enzymes in both physiological and pathological tissue
degradation [1–3]. Other members of the family include
stromelysin-2, stromelysin-3, fibroblast and neutrophil
collagenases, gelatinases A and B, matrilysin, the newly
discovered collagenase-3 [4] and membrane-type matrix
metalloproteinase [5]. MMPs play important roles in
matrix remodelling events during tissue morphogenesis
and wound healing. The specific collagenases have inter-
stitial collagen as their principal substrate, the gelatinases
degrade denatured collagen, while the stromelysins have a
broader proteolytic profile. Stromelysin is unique among
MMPs in its involvement in the regulation of the other
members of the family by activating their proenzymes.
Stromelysin has also been implicated in the catabolism of
cartilage proteoglycan aggregate structures [6]. Uncon-
trolled metalloproteinase activity can cause extensive
tissue damage resulting in a range of pathological
processes involved in tissue degenerative diseases as
diverse as arthritis and cancer. Thus, MMPs are extremely
important medicinal targets in the rational design and
synthesis of selective inhibitors.
The potential utility of MMP inhibitors in controlling a
wide range of diseases has stimulated extensive struc-
ture/function studies on several series of peptidomimetic
compounds. MMP inhibitors have been shown to reduce
growth and invasiveness in tumorigenic cells in in vivo
models [7], decrease tumour burden and prolong the sur-
vival of mice bearing human ovarian carcinoma xenografts
[8] and suppress the development or reverse autoimmune
encephalomyelitis [9]. It has been demonstrated that
tissue inhibitors of metalloproteinases, TIMP-1 and
TIMP-2, as well as a synthetic MMP inhibitor, prevent
collagen and proteoglycan degradation in nasal cartilages
[10,11]. The recent discovery of peptide hydroxamates in
inhibiting tumour necrosis factor-a (TNF-a) convertase
[12–14] suggests that TNF-a convertase may be a new
member of the MMP family (sequence unpublished), thus
broadening the use of MMP inhibitors.
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MMPs are members of a superfamily of zinc endo-
peptidases collectively referred to as ‘metzincins’ [15].
These enzymes share the elongated zinc-binding motif
HExxHxxGxxH and a 1,4 b-turn (Met-turn) that brings an
invariant methionine residue close to the catalytic zinc ion
and brings neighbouring conserved residues into a posi-
tion where they interact with the substrate or inhibitor
[16]. They have a multi-modular architecture with a signal
peptide for secretion, a propeptide for maintaining
enzyme latency, a zinc-binding catalytic domain for enzy-
matic activity, and (with the exception of matrilysin), an
additional haemopexin-like C-terminal domain presum-
ably involved in preferential substrate binding. Gelati-
nases have two further domains: a fibronectin-type
gelatin-binding domain inserted within the catalytic
domain and an extra collagen-like insert between the cat-
alytic domain and the C-terminal domain. Activation
involves the removal of the propeptide resulting in expo-
sure of the active site presumably through the ‘velcro’ (or
cysteine-switch) mechanism in which a thiol ligand of the
catalytic zinc ion (donated by a highly conserved and
unpaired cysteine residue in the propeptide) is lost [17]. 
The MMP catalytic domain is sufficient for enzymatic
cleavage of peptide and protein substrates [18–22],
although the C-terminal domain is required for colla-
genase to degrade helical collagens [23,24] and is involved
in binding with TIMPs [25,26]. Full-length MMPs are
present in minute amounts in tissues and their inherent
flexibility has made them difficult to crystallize. Porcine
synovial collagenase is the only member of the family to
have yielded stable crystals of the full-length enzyme suit-
able for X-ray analysis [27]. Expression of the catalytic
domains of MMPs creates stable proteins for structural
studies because the flexible linkers between domains and
the autolytic sites in the C-terminal domain are removed.
Such truncated enzymes have also proved useful for
screening in drug discovery. Hence, initial structural
studies have aimed to characterize the catalytic domain.
X-ray structural studies of N-terminal catalytic domains of
MMPs include those of human fibroblast collagenase
[28–31], neutrophil collagenase [32–34] and matrilysin
[35]. The NMR structure of the catalytic domain of
human stromelysin-1 has also been reported [36]. There
have been structural studies of more distantly related met-
zincins such as crayfish digestive enzymes (astacin [37]),
snake venom metalloproteinases (adamalysin [38] and
atrolysin [39]) and the large bacterial enzymes also known
as serralysins (Pseudomonas aeruginosa alkaline proteinase
[40] and Serratia marcescens proteinase [41]). Although the
structures of several MMP catalytic domains were
reported in late 1993 and early 1994, their coordinates
were not available when our structural studies on the
stromelysin catalytic domain were carried out.
Here we describe the X-ray analysis of the three-dimen-
sional structure of stromelysin-1 catalytic domain (SCD)
complexed with a hydroxamate inhibitor (PD-140798),
extending from P1′ to P3′, refined to 2.0 Å resolution and
its comparison with the solution structure [36]. We also
present a detailed comparison of the structure with repre-
sentative structures of collagenases, other metzincins
(astacin, adamalysin, serralysin) and thermolysin [42].
Results and discussion
Tertiary structure
The SCD (comprising residues 83–249) adopts a roughly
ellipsoidal shape as shown in Figure 1. Three-quarters of
the protein (Pro90–Gly207) form the left lobe with an
open-sandwich topology composed of two a-helices
packed against a twisted, five-stranded b-sheet (Fig. 2a).
As in the other matrixin structures, the b-sheet is com-
posed of four parallel strands and one antiparallel strand.
The amphipathic helix aA, separating strands b1 and b2,
extends the full length of the b-sheet while the second
helix aB follows strand b5 and harbours the two conserved
histidine residues that ligate the catalytic zinc ion. The
right lobe, formed by the rest of the catalytic domain,
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Figure 1
Stereoview of the SCD Ca trace. The two
zinc ions are shown as green spheres and the
three calcium ions as red spheres. The
residue numbering is based on the mature
stromelysin-1 sequence.
consists of a series of turns culminating in a long helix aC
at the C terminus which is in close proximity to the
N terminus at the surface. Only three residues of the
flexible loop following helix aC are well ordered. The two
lobes are separated by a flat active site. The sequential
order of secondary structural elements is shown schemati-
cally in Figure 2b. 
Density corresponding to a tripeptide fragment (FPG)
probably resulting from a double cleavage of the first
seven residues (FRTFPGI) of the SCD could be seen in
the difference maps, bound securely near the N terminus
of molecule A (one of the two molecules in the asymmet-
ric unit). The residues adjacent to the two proposed
cleavage sites, Thr-Phe and Gly-Ile, correspond to sub-
strate sequences generally preferred by matrixins at P1
and P1′ positions. The N terminus of the fragment forms
a salt bridge with the carboxylate of a conserved aspartate
residue from the C-terminal helix aC in a fashion similar
to that found in the structures of neutrophil collagenase
catalytic domain [33] and matrilysin [35]. The tripeptide
is linked by hydrogen bonds to residues 210–212 to form
a short twisted b-sheet as in matrilysin. The location of
the fragment is very close to the active site, consistent
with autolytic cleavage. This is also consistent with the
NMR structure of SCD [36], for which nuclear Over-
hauser enhancements (NOEs) were observed between
the N-terminal Phe83 and the imidazole ring of His205
that ligates the active-site zinc. Moreover, this implies
that the N termini of the active matrixins are close to the
active site, as would be expected for the cysteine-switch
mechanism. In the present crystal structure, the N termi-
nus of the contiguous protein chain starts with Pro90 in
both molecules of the asymmetric unit. This is similar to
the situation found in certain collagenase structures in
which residues preceding the analogous proline were
found to be disordered.
Metal coordination
The catalytic zinc is located below the active-site cleft as
in the other MMP structures and has a pentagonal coordi-
nation mediated by three histidines (His201 Ne2, His205
Ne2, His211 Ne2) and both the hydroxamate oxygens of
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Figure 2
Schematic representations of SCD structure. (a) Cartoon of the
SCD–inhibitor complex (drawn using SETOR [58]). The hydroxamate
inhibitor is shown as a stick model (magenta). The zinc ions are shown
in green while the calcium ions are coloured red. Side chains ligating
the two zinc ions and the invariant methionine residue (dark green),
which forms the base of the catalytic zinc site of the metzincins, are
also shown. (b) Schematic representation of the secondary structure
of SCD. Residues in helices are enclosed in oval boxes while those in
b-strands are surrounded by rectangular boxes. Hydrogen bonds to
main-chain atoms are represented by arrows from the donor to the
acceptor.
the bound inhibitor. 2|Fo|–|Fc| density surrounding the
catalytic zinc ion is shown in Figure 3. The second zinc
ion, unique to MMPs, is confined to the surface above the
five-stranded b-sheet by the loop linking strands b3 and
b4 that arches over strand b5. It is bound in a tetrahedral
configuration by Asp153 Od2, His151 Ne2, His166 Ne2
and His179 Nd1. 
The structure also contains three octahedrally coordinated
calcium ions. Two of them, Ca1 (bound to Asp158 Od1,
Gly159 O, Gly161 O, Val163 O, Asp181 Od2, Glu184 Oe2)
and Ca2 (bound to Asp141 O, Gly173 O, Asn175 O,
Asp177 Od1 O and two water oxygens), are located on
either side of a long S-shaped arrangement of loops and
strands formed by the loop bridging the strands b3 and b4
on one side and the loop linking b4 and b5 on the other.
The third calcium ion, Ca3, (bound to Asp107 Od1,
Asp107 Od2, Asp182 Od1, Glu184 O and two water
oxygens) is located about 10 Å away from Ca1 in an adja-
cent loop linking b5 to helix aB. The residues that bind
Ca1 and Ca2 belong to two glycine-rich sequences
(D*G*PG*NV* and PGPG*IN*GD*, where * denotes
liganding residues) which are conserved in the matrixins
and are reminiscent of the haemolysin-type calcium-
binding repeats found in the C-terminal extension of
alkaline protease [40] and serralysin [41].
Active site
The active-site cleft of SCD runs approximately parallel
to the five-stranded b-sheet with strand b4 and helix aB
forming one edge. The opposite side is bordered mainly
by the 1,4 b-turn with the conserved methionine (the
Met-turn). Unlike the aspartic proteinases, the cleft is
shallow in the zinc metalloproteinases. The inhibitor
PD-140798 occupies only the prime side of the active site.
The non-prime region of the active site is partially occu-
pied by an exposed loop of the non-crystallographically
related molecule, as discussed below. 
Inhibitor binding
The tripeptide hydroxamate inhibitor spans the S1′ to S3′
subsites of SCD and adopts an extended conformation
with the two hydroxamate oxygens ligating the catalytic
zinc. In addition to the metal chelation, the inhibitor back-
bone is held in position by hydrogen bonding and van der
Waals interactions with the protein backbone of strand b4
on one side and the residues adjacent to Pro221 on the
other (see Fig. 4). The main chain of the inhibitor forms 
a complementary strand to the ‘edge strand’ b4. Five
hydrogen bonds are formed between the inhibitor main
chain and the protein while the C-terminal amide group
interacts with water molecules and a symmetry-related
neighbouring molecule.
The S1′ subsite in stromelysin is predominantly hydro-
phobic in composition. The P1′ leucine of the inhibitor 
is surrounded by residues Leu164, Val198, Pro221 and 
Tyr223 which are highly conserved among the matrixins. 
However, the pocket is much deeper in comparison with 
the collagenases and is filled by a network of water 
molecules which extends right through to the surface of 
the molecule. This accounts for the recent experi-
mental demonstration that stromelysin and gelatinase can 
accommodate extended hydrocarbon and v-amino hydro-
carbon chains in their S1′ pockets [43], whereas fibroblast 
collagenase cannot. 
A comparison of the crystal structure of fibroblast colla-
genase [30] (Protein Data Bank [44] entry 1hfc) and SCD
in the vicinity of the S1′ pocket (illustrated in Fig. 5)
reveals that Arg214 (fibroblast collagenase numbering) of
the collagenase structure forms the bottom of the S1′
pocket, whereas in the SCD crystal structure, the corre-
sponding residue, Leu197, is swung away to reveal the
water-filled channel running through the enzyme.
Among the matrixins, Arg214 is found only in fibroblast
collagenase. Neutrophil collagenase has a larger S1′
pocket than fibroblast collagenase because, like SCD, it
has a leucine in the corresponding region. Another factor
contributing to the increase in the size of the S1′ subsite
is the insertion of three residues following Thr227 
in stromelysin. Neutrophil collagenase and matrilysin 
have two residues inserted in equivalent positions. 
However, the insertion region is not in direct contact
with the P1′ residue.
The P2′ leucine of the inhibitor finds complementary
contacts with residues such as Val163 and Leu222 lining
the relatively shallow S2′ subsite. In contrast to S1′, the
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Figure 3
Difference map, computed with coefficients 2|Fo|–|Fc|, showing the
environment around the catalytic zinc ion.
residues in contact with the inhibitor in this subsite differ
significantly even among the closely related matrixins
such as neutrophil collagenase and fibroblast collagenase,
as seen in Table 1. 
The S3′ subsite is also relatively shallow in SCD as in the
catalytic domains of other collagenases. The P3′ phenyl-
alanine interacts with a tyrosyl side chain (Tyr223) from
the conserved Met-turn. The corresponding tyrosine in
collagenase complexes has a different orientation which is
accomplished by a rotation about x1. Modelling studies
show that Tyr223 can also close the active site by adopting
an alternative arrangement about x1 (see also the NMR
ensemble reported in [36]). Tyr223 is highly conserved
among the matrixins and its conformational flexibility sug-
gests that it may play the role of a selective gatekeeper to
the active site.
Non-crystallographic symmetry
The two molecules in the asymmetric unit of the SCD
complex are related to each other by a rotation of 179.2°
about a local twofold axis. Although the two molecules
were refined independently, the overall structures are
almost identical (root mean square deviation [rmsd]
0.23 Å) but for a few loop regions involved in contacts with
symmetry-related molecules. In particular, the N-terminal
tripeptide fragment seen in molecule A is not observed in
the non-crystallographically related molecule B. The crys-
tallographic dimer is stabilized by many interactions
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Figure 4
Schematic cartoon of the SCD active site and
its interactions with the hydroxamate inhibitor,
PD-140 798 in cyan. 
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Figure 5
A comparison of the active sites of SCD (cyan) and fibroblast
collagenase (yellow), showing the binding subsites S1′–S3′ in the two
enzymes. Cut-away views of the enzymes and their associated
Connolly surfaces are shown. Note the replacement of a leucine (197)
in SCD by an arginine (214, in collagenase numbering), effectively
blocks the bottom of the specificity pocket in fibroblast collagenase. 
In SCD, the S1′ pocket leads to a water-filled channel running through
the enzyme to the external solvent.
including those mediated by water molecules at the inter-
protomer interface. The catalytic domain monomer has
several aromatic and hydrophobic residues exposed at the
surface which presumably interact with the other domains
in the full-length enzyme. The formation of the dimer
buries many of these residues in the interface. 
Another interesting feature of the non-crystallographic
symmetry is that it brings the catalytic sites of the two
molecules close to each other. Four residues (D153FYP) of
an exposed loop in molecule B interleave into the non-
prime substrate-binding site of the pseudo-twofold-
related counterpart to form an almost mouth-to-mouth
dimeric arrangement. The positioning of these residues is
such that the proline residue (Pro156) fills part of the S1
subsite while the phenylalanine residue (Phe154) partially
occupies the S3 subsite. This arrangement is stabilized by
hydrogen-bonding interactions between the hydroxyl
oxygen of Tyr155 and the edge strand b4, mediated by a
water molecule. However, the orientation of these
residues is very different from the extended conformation
of substrate binding. The hydroxamate inhibitor lies on
the opposite (prime) side.
Comparison with NMR-derived structures
Figure 6 shows a comparison of the Ca trace of the crystal
structure with the ensemble of 15 structures of an
SCD–inhibitor complex derived from NMR data using
~1200 NOE restraints (PDB entry 1srt) [36]. Significant
differences between the crystal structure and the NMR
ensemble are observed in the loops connecting Phe157 to
Val163, and Ser225 to Phe232. The first loop has a bound
calcium ion in the crystal structure; the restraints corre-
sponding to calcium–protein interactions were presumably
not used in the NMR analysis. The second loop, located
near the entrance to the active site, shows considerable
conformational variability in the NMR structures. The
active-site residues align quite well, the only significant
differences occurring deep in the S1′ pocket. 
Comparison with other metalloendopeptidases
The overall topology of the SCD is identical to that of the
collagenases and the other metzincins and highly similar to
that found in the more distantly related bacterial metallo-
proteinase, thermolysin. However, the non-MMP enzymes
either have additional or missing secondary structural ele-
ments. Table 2 presents the results of the comparison of
representative X-ray structures of the N-terminal catalytic
domains of MMPs with other metzincins and thermolysin.
The pairwise sequence identities are seen to correlate rea-
sonably well with the rmsds. The figures show a distinct
demarcation between the MMPs and the other metzincins.
It is interesting to note that adamalysin and thermolysin
are equally distant from the other structures in spite of the
fact that one is a metzincin while the other is not. This is
also reflected in the clustering pattern observed in the phy-
logenetic tree (Fig. 7). The structural comparisons clearly
emphasize the similarity in the overall tertiary structures of
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Figure 6
Comparison of the SCD crystal structure
(cyan tube threaded through the backbone
atoms) with Ca traces of the ensemble of 15
structures derived from NMR data (thin lines).
Two zinc (green) and three calcium (red) ions
from the SCD crystal structure are shown, as
is the inhibitor PD-140 798 (stick model). The
arrows indicate areas of significant deviation
between the crystal structure and the NMR
ensemble at residues 157–163 (top arrow)
and 225–232 (bottom arrow).
Table 1
Residue differences among matrixins in the specificity
subsites.
Pocket scda 1hfc 1mnc Matrilysin
S1′ subsite Leu197 Arg Leu Tyr
S2′ subsite Asn162 Gly Gly Asn
Val163 Asn Ile Thr
Leu222 Ser Asn Thr
His224 Thr Ala Gly
S3′ subsite Gly192 Glu Asn Leu
Thr193 Tyr Gly Tyr
Abbreviations: scda, stromelysin-1 catalytic domain (molecule A); 1hfc,
human fibroblast collagenase; 1mnc, neutrophil collagenase.
the zinc metalloendopeptidases which might be the result
of divergent evolution from a common ancestor.
A more detailed comparison of these sequences with their
structures is shown in the alignment generated using
COMPARER [45] symbolized by the JOY [46] format
(Fig. 8). This alignment not only illustrates the conserva-
tion of the key secondary structural elements but also
highlights the differences in the length and composition
of the intervening loop regions. These sequence differ-
ences are manifested in the structural disposition of the
secondary structural elements, as seen in Figure 9.
The major variations in the sequences of matrixins are
clustered in two regions (residues 189–193 and 224–231).
These structurally variable regions occur in the loops that
connect strand b5 to helix aB (VR1) and the Met-turn to
helix aC (VR2), respectively. They are solvent-exposed
surface loops located on either side of the mouth of the
active site (Fig. 10). These regions exhibit the highest
structural deviation among the proteins compared in
Figure 7 and even differ in the two closely related collage-
nases. VR1 is the site of the fibronectin-type insert in the
gelatinases while VR2 corresponds to an insertion region
for the stromelysins among the matrixins and, as men-
tioned in an earlier section, it shows conformational varia-
tions. This region was also reported to have high mobility
in the catalytic domain of neutrophil collagenase [34]. The
COMPARER alignment shows that the lengths of the
equivalent loops vary substantially among the metallo-
proteinases. Thus, astacin and adamalysin have short loops
connecting strand b5 and helix aB (VR1) while astacin and
thermolysin have very long segments inserted between
the Met-turn and helix aC (VR2). Substrate modelling
indicates that these regions could indeed be the main
determinants of the substrate selectivity among matrixins.
It is interesting to note that VR2 is spatially adjacent to
the four-bladed b-propeller-shaped haemopexin domain
of porcine synovial collagenase [27] which has been impli-
cated in substrate binding. 
Regulation of activity by metal ions
Many experimental studies, including those on the gelati-
nase catalytic domain performed in this laboratory [22,47],
have shown that MMPs require both zinc and calcium ions
for catalytic activity as well as structural stability. As the
concentrations of both calcium and zinc ions fluctuate
markedly according to a cell’s surroundings and the
processes in which it is participating, cation binding might
provide an extremely efficient stratagem for controlling
non-specific proteolytic activity of these lethal enzymes.
In this way, the concentrations of zinc and calcium ions 
in the medium might be additional determinants of the
functional state of the enzyme’s active site. 
The structural zinc is found only in MMP catalytic
domains among metzincins. The four residues which
chelate this zinc, although highly conserved among the
matrixins, have no counterparts in the other metzincins as
can be seen from Figure 8. In adamalysin, the position of
the structural zinc is occupied by a helix which is not
present in any of the other metzincins (as seen in Fig. 8).
Thus, this zinc ion seems to have a purely structural role
and may not play a part in the catalytic mechanism.
Two of the calcium ions, Ca1 and Ca2, have their binding
sites at opposite ends of the antiparallel b-strand that
marks the boundary of the substrate-binding cleft. There
may be conformational changes in the absence of these
calcium ions that might impair substrate binding. Hence
calcium ions may be essential for maintaining the shape
and volume of the binding site. 
Research Article Stromelysin catalytic domain structure Dhanaraj et al. 381
Figure 7
Dendrogram depicting the clustering of the structures of the
metalloproteinase superfamily. The horizontal distances between pairs
of enzymes and their common branching points are measures of their
structural differences.
3tln Thermolysin
1iag Adamalysin
1ast Astacin
1srp Serralysin
scda Stromelysin
1mnc N. collagenase
1hfc F. collagenase
Table 2
Comparison of sequences and coordinates of N-terminal
catalytic domains of MMPs with those of other metzincins and
thermolysin.
Protein scda 1hfc 1mnc 1srp 1ast 1iag 3tln
scda – 0.56 0.62 1.38 1.63 1.98 1.96
1hfc 62.6 – 0.55 1.37 1.77 1.92 2.09
1mnc 57.1 66.5 – 1.45 1.73 1.89 2.07
1srp 26.2 28.8 25.7 – 1.63 2.12 1.96
1ast 22.8 18.9 16.4 17.8 – 2.05 2.02
1iag 16.5 12.4 13.4 10.3 14.1 – 2.00
3tln 15.2 19.8 12.1 9.9 8.2 12.2 –
Values above the diagonal are rmsds (in Å) derived from superposition of
Ca atoms using a 3.5 Å cutoff for pairs of equivalent residues. Values
below the diagonal are pairwise sequence identities (%). Protein codes
are as follows: scda, stromelysin-1 catalytic domain (molecule A); 1hfc,
human fibroblast collagenase; 1mnc, neutrophil collagenase; 1srp,
serralysin (residues 4–253; the region 254–471 consisting of the calcium-
binding parallel b-roll repeats has been omitted from the comparison);
1ast, astacin; 1iag, adamalysin; 3tln, thermolysin (residues 1–288). 
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Figure 8
Structural alignment of MMPs with other metzincins and thermolysin
generated using COMPARER symbolized by the JöY format. Ligands
to the zinc ions are enclosed in grey-outlined boxes while sequences
corresponding to the calcium-binding loops are enclosed in black-
outlined boxes. The variable regions VR1 (189–193; SCD numbering)
and VR2 (224–231; SCD numbering) are bounded by dashed lines.
The protein codes are the same as those given in Table 2. The key to
the alignment is as follows: UPPER CASE, solvent inaccessible; lower
case, solvent accessible; bold type, hydrogen bond to main-chain
amide; ____underline____, hydrogen bond to main-chain carbonyl; tilde,
hydrogen bond to side chain; italics, positive f; çedilla, disulphide
bridged half-cysteine; breve, cis-peptide. 
Biological implications 
Stromelysin is a zinc-dependent endopeptidase
belonging to the family of matrix metalloproteinases
(MMPs, matrixins) which play critical roles in the
breakdown of extracellular matrix components
during tissue growth and repair. Stromelysin is
unique among MMPs in its involvement in the regu-
lation of the other members of the family (by activat-
ing their proenzymes) and its ability to degrade
proteoglycans. Hence it is an important target in the
design of drugs to combat a wide spectrum of tissue
degenerative diseases. 
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Figure 9
Schematic illustrations of the structures of representative members of
the zinc metalloproteinase superfamily. The zinc ions are displayed as
green spheres, calcium ions as red spheres and the disulphide bridges
as yellow spheres. The hydroxamate inhibitor, shown with magenta
bonds, identifies the active site in SCD. Side chains ligating the zinc
ions and the invariant methionine are also shown. (Figure produced
using MOLSCRIPT [59].)
Figure 10
The ‘jaws’ of metalloproteinases. A comparison of the variable regions
VR1 and VR2 in matrixins seen in the structural superposition of Ca
traces of the catalytic domains of stromelysin (white), fibroblast
collagenase (green) and neutrophil collagenase (yellow). Side chains
are coloured by residue type while their labels are in the same colour
as the corresponding Ca trace. The active site is represented by the
hydroxamate inhibitor (purple). The calcium ion Ca1 which stabilizes
the edge strand b4 is seen as a red sphere at the top left.
The catalytic domains of MMPs share the extended
zinc-binding motif ‘HExxHxxGxxH’ with the met-
zincins and adopt an open-sandwich structure in
which two a-helices pack against a twisted five-
stranded b-sheet. The overall fold is significantly
similar to that of more distantly related bacterial
enzymes. The crystal structure of the stromelysin cat-
alytic domain presented here augments the structural
database of matrixins and metzincins to give a more
detailed picture of similarities and differences among
members of the zinc metalloproteinase superfamily. 
Comparisons of the stromelysin catalytic domain
with other members of the metalloproteinase super-
family highlight the conservation of key secondary
structural elements as well as the differences in the
loop regions linking them. In spite of striking similari-
ties in the overall topology there are significant differ-
ences between stromelysin and the other MMPs, not
only in peripheral regions but even in the specificity
pockets. Even among closely related matrixins, the
S1′ pocket and the ‘jaws’ regions are capable of
assuming variable conformations, contain insertions
and deletions, and are able to accommodate a variety
of inhibitor moieties. A detailed analysis of these dif-
ferences will provide an excellent basis for the ratio-
nal design of specific inhibitors targeted to individual
members of the family. 
Materials and methods
Expression, crystallization, heavy-atom derivatives and data
collection
The expression and purification of the human stromelysin-1 catalytic
domain has been described previously [19]. The catalytic domain, con-
sisting of residues Phe83–Pro256 of full-length stromelysin, was
expressed in Escherichia coli in an insoluble form and refolded in vitro
to the active form in high yield. The purified enzyme was able to
degrade several peptide and protein substrates, including its natural
substrate proteoglycan, and was remarkably stable at 37°C, even in the
absence of an inhibitor.
Crystallization of the stromelysin catalytic domain was carried out 
over a range of pH values from 5.5–7.0 using polyethylene glycol 
(PEG), 2-methyl-2,4-pentane diol (MPD) and ammonium sulphate as
precipitants. Several different crystal morphologies were obtained.
Crystals of SCD with a hexagonal bipyramidal morphology (average
crystal dimensions: 0.3 × 0.2 × 0.2 mm3), obtained by hanging-drop
vapour diffusion from ~10 mg ml–1 protein solution in 50 mM Tris-HCl
in the presence of a hydroxamate inhibitor (at twice the molar concen-
tration of the protein) and 10 mM CaCl2 using PEG 6000 were chosen
for initial structural studies. These crystals belong to the space group
P61 with cell dimensions: a=b=77.6 Å, c=117.9 Å, a=b=90°, g=120°
and contain two molecules per asymmetric unit, corresponding to a
solvent content of 54%. Heavy-atom reagent solutions (5–10 mM)
were prepared in the stabilizing buffer containing PEG 6000, and the
crystals were soaked for a period of 12–48 h.
Intensity data were collected from native and heavy-atom soaked crys-
tals using the MAR Research imaging plate on the Doris beamline BW6
at DESY, Hamburg at a fixed wavelength of 0.96 Å and a temperature of
~6°C. The details of the crystals and the intensity data are shown in
Table 3. Most of the data sets were processed using MOSFLM [48]
and CCP4 software [49]. A large crystal (1.2 × 0.6 × 0.6 mm3) of the
inhibitor complex with identical morphology and similar unit cell dimen-
sions (a=b=77.6 Å, c=114.96 Å, a=b=90°, g=120°) was obtained
serendipitously from a ~40 mg ml–1 solution of SCD (in Tris-HCl, pH
7.0, containing 10–15% acetonitrile and 20 mM CaCl2) in an NMR tube
used for structural studies. Data from this crystal were collected on an
in-house MAR Research imaging plate mounted on a rotating anode
X-ray source and processed using MARXDS [50].
Structure solution
The structure was solved by multiple isomorphous replacement (MIR).
The CCP4 software suite was used for scaling the derivative data sets,
computing difference Patterson maps and subsequent refinement.
Heavy-atom sites were refined using VECREF [51] and MLPHARE
[52]. Inclusion of anomalous scattering data validated the choice of
P61 as the space group rather than its enantiomorph. The refined
phases were improved by subsequent solvent-flattening and phase-
extension cycles [53] to 3.2 Å to produce an electron-density map
which showed most of the secondary structure. Chain tracing and
model building were carried out using the interactive graphics software
O [54]. The coordinates of the catalytic domain of human fibroblast
collagenase (1hfc) released at this stage by the Protein Data Bank [42]
aided the manual rebuilding of the two molecules in the asymmetric
unit from electron density computed using MIR phases. 
Refinement
Least-squares refinement of the two molecules as rigid bodies using
RESTRAIN [55] gave a crystallographic R-factor of 0.41 and a correla-
tion coefficient of 0.53. The difference maps, computed with coeffi-
cients |Fo|–|Fc| and 2|Fo|–|Fc|, and the calculated phases, allowed five
metal ions (two zinc and three calcium) and the inhibitor (not included
in the rigid-body refinement and phase calculation) to be clearly identi-
fied. After a few rounds of manual rebuilding and least-squares refine-
ment using RESTRAIN, the current R-factor and correlation coefficient
are 0.19 and 0.95 respectively at 2.0 Å resolution.
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Table 3
Details of the X-ray intensity data and heavy-atom parameters.
Data processing Heavy-atom parameter
dmax Rmerge Number of Completeness Soak Number RCullis Phasing
reflections (%)* time of sites power†
SCD complex 2.4 Å 0.12 7833 88.4 (4.9) – – – –
Pb(OAc)2 5 mM 3.3 Å 0.21 6038 100.0 (5.5) 12 h 2 0.7 1.26
K2PtCl4 10 mM 3.3 Å 0.14 5466 98.1 (5.5) 2 days 1 0.8 1.01
Crystal from NMR tube 2.0 Å 0.08 25 278 98.1 (5.2) – – – –
*Figures in parentheses indicate multiplicity of observations. †Phasing power=<FH>/E, where FH is the heavy-atom structure-factor amplitude, and
E is the residual lack of closure error.
Comparisons and phylogenetic tree
COMPARER [45] was used to derive a multiple alignment of metallo-
proteinase three-dimensional structures based on numerous criteria such
as residue identity, residue-type properties, local fold, solvent accessi-
bilities, hydrogen-bonding relationships and hydrophobic contacts. The
alignment thus generated is symbolized by the JOY [46] format, which
allows the structural environment at each position to be visualized using
a modified representation of the standard one-letter amino acid code.
Using the structural alignment, clustering methods can then be applied
to generate a matrix of similarity scores between all pairs of the struc-
tures being compared [56]. The information contained in the matrix 
is used to obtain a dendrogram using KITSCH [57], a program from
the Phylogenetic Inference Package (PHYLIP). The dendrogram is con-
structed such that the difference between the distances in the dendro-
gram and those in the dissimilarity matrix is minimal. The program
DRAWTREE (Z-Y Zhu, unpublished program) was used to produce the
LATEX version of the dendrogram. 
The stromelysin catalytic domain coordinates have been deposited with
the Brookhaven Protein Data Bank.
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